Galderma has announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel. Mirvaso is an alpha-2 adrenergic receptor agonist that acts rapidly and can

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In